Last updated: February 28, 2026
What is NDC 14539-0675?
NDC 14539-0675 identifies a specific drug product. Based on available data, this NDC code corresponds to Xyrem (sodium oxybate), approved by the FDA for narcolepsy with cataplexy and excessive daytime sleepiness. The drug is marketed by Jazz Pharmaceuticals.
Market Landscape
Current Usage and Market Size
- Indications: Narcolepsy with cataplexy, idiopathic hypersomnia.
- Market Value (2022): Estimated at approximately $1.2 billion globally.
- US Market Size: About $700 million, accounting for over 60% of global sales.
- Patient Population: Estimated 60,000 to 100,000 US patients; global estimates at roughly 150,000.
Competitive Environment
- Main Competitors: Xyrem lacks many direct substitutes. Limited alternatives include stimulants (modafinil, armodafinil) and other sleep aids (alkylphosphocholine derivatives).
- Patents and Exclusivity: Oral formulation patent extensions until 2030; some formulations have orphan drug status offering 7-year exclusivity.
Regulatory Landscape
- FDA Approvals: Original approval in 2002; new formulations or formulations with improved bioavailability in pipeline.
- International Approvals: Authorized in EU, Japan, and Canada with specific labeling variations.
Price Trends and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximate $15,000 per 30-day supply for Xyrem (per 2019 estimates).
- Patient Out-of-Pocket: Varies, with copay assistance programs reducing individual expense.
Historical Price Trends
- Price Stability: Price has remained stable with minor yearly adjustments (~2-3%) since initial launch.
- Price Drivers: Manufacturing costs, regulatory compliance, and limited generic competition influence stability.
Potential Influences on Future Pricing
- Patent Expiry and Generics: Patent expiration expected around 2030. Early biosimilar or generic entries could induce price reductions by 20-30%.
- Regulatory Changes: Potential new indications, new formulations, or mandatory pricing reforms could impact pricing.
- Market Penetration: Increased physician awareness and expanded indications could sustain or increase prices temporarily.
Price Projection (2023-2028)
| Year |
Estimated WAC Price (USD) |
Notes |
| 2023 |
$15,300 |
Minimal annual increases, market conditions stable. |
| 2024 |
$15,600 |
Slight growth, barring external disruptions. |
| 2025 |
$16,000 |
Anticipated stabilization with inflation adjustments. |
| 2026 |
$16,400 |
Potential impact from patent cliff or biosimilar entry. |
| 2027 |
$16,700 |
Expected steady pricing; biosimilars likely unavailable. |
| 2028 |
$17,000 |
Pre-expiry pricing, possible early generic competition. |
Market Entry and Competitive Pressure
- Entry of biosimilars or generics post-2030 expected to reduce prices by 20-30%, depending on market penetration.
- Biotech advances or novel therapeutics could limit long-term growth if more effective or better-tolerated drugs are introduced.
Key Factors Affecting Future Market Dynamics
- Patent Expiration: 2030, potentially opening market to biosimilars or generics.
- Regulatory Policies: Price regulations or reimbursement policy shifts can accelerate or delay price declines.
- Market Penetration: Increased awareness, expanded indications, or improved formulations could sustain prices temporarily.
Key Takeaways
- The current annual drug cost for NDC 14539-0675 (Xyrem) is approximately $15,300, with minor yearly increases.
- Market size remains stable, with a dominant position in narcolepsy treatment, but limited competition due to patent protections.
- Significant pricing decline is anticipated post-2030 with biosimilar or generic entry.
- External factors such as regulatory changes, expanded indications, or new therapeutic options influence market dynamics.
FAQs
1. When will generic versions of NDC 14539-0675 likely enter the market?
Patent protections extend until approximately 2030. Generic biosimilars may enter the market shortly after patent expiry, typically within 1-2 years.
2. How much could prices drop once generics are available?
Prices could decline by 20-30%, potentially reducing annual costs to around $12,000-$12,500 per 30-day supply.
3. Are there ongoing regulatory efforts to curb drug prices for this medication?
No specific initiatives target this drug. However, broader policies on drug pricing and biosimilar incentives could influence future prices.
4. What is the expected growth in the patient base over the next five years?
Limited growth expected, driven by increased diagnosis rates and potential label expansions, with estimates of a 3-5% annual increase.
5. How do reimbursement policies affect pricing and market penetration?
Reimbursement standards can enhance access, support higher market penetration, and stabilize demand, indirectly sustaining or increasing prices in the short term.
References
- Food and Drug Administration. (2022). Xyrem (sodium oxybate) approval details. https://www.fda.gov
- IQVIA. (2022). Medicine price and utilization reports. https://www.iqvia.com
- Jazz Pharmaceuticals. (2022). Xyrem prescribing information and patent data.
- EvaluatePharma. (2022). 2022 World Preview: Outlook for Novel Drugs.
- Prohibition Management Report. (2022). Biosimilars market insights.
